What Has Changed For Ascentage Pharma Since Its 56% Fall

If you had looked at Ascentage Pharma Group International in October 2025 and decided not to buy, that choice spared you a difficult ride. For Ascentage Pharma Group International shareholders, the loss over the past year was 56.4%, including dividends. The period included upbeat ASCO and EHA 2026 data and higher first half 2026 revenue, but also deeper losses and a weaker net margin. Which warning sign in the earlier Takeda and NRDL reliance debate would you have scrutinized most?

On Simply Wall St, a Narrative is an investor's thesis written down: the reasoning, plus the numbers it rests on. Run those numbers and you get an estimated Fair Value.

Ascentage Pharma Group International has already moved. Pinpoint other ways to investigate the theme among 127 healthcare AI stocks.

The Two Stories Investors Had To Weigh On Ascentage Pharma Group International

The shares cost HK$72.5 at the start of the period, and anyone looking at Ascentage Pharma Group International then had to decide which story felt more convincing.

The bullish narrative put Fair Value at HK$92.81, anchored on the Takeda alliance, NRDL inclusion, and an assumption that revenue would climb 74.7% with profit margin reaching 38.3% within three years.

The bearish view saw Fair Value at HK$51.97, focused on dependence on one off Takeda payments and an assumption that revenue would decline 3.7% while margin moved to 18.6% on a much higher future P/E of 136.5x.

What The Results Changed For Ascentage Pharma Group International

The most striking update for Ascentage Pharma Group International was clinical progress at ASCO and EHA 2026, where olverembatinib and lisaftoclax produced strong response data and kept the Takeda partnership story alive, which leaned toward the optimistic case. At the same time, revenue moved from CNY233.7m to CNY302.2m while the company still reported a larger loss and a weaker net margin, which left the profitability claim unproven. Overall, the evidence cut both ways.

The useful takeaway is about what to check first. When a bullish pitch leans on future high margins and one key partner, track two items in later filings: the trend in net margin and how much of sales still depend on that partner or product.

What You Would Be Paying For In Ascentage Pharma Group International Today

Ascentage Pharma Group International now trades at HK$29.74, so the share price is down 56.4% over the past year. The selected Narrative's Fair Value sits above the current price and relies on late stage trial execution rather than earlier partnership hopes.

For the fall to look like an opportunity rather than a warning, a buyer today would need to believe lisaftoclax and olverembatinib can progress through late stage trials into approvals, with rising R&D and selling costs remaining manageable.

"The key requirement for this outlook is the successful execution of the late-stage lisaftoclax and olverembatinib trials, including GLORA-4, POLARIS-1 and POLARIS-2, while also managing rising R&D and selling expenses."

One Narrative has put a figure on that disagreement. → See the Narrative with its higher Fair Value, assumptions and all

Go Straight To The Source

The next headline does not have to be where your research begins. Go straight to the companies and see whether a contrarian opportunity could be taking shape.

• Company 1 - 44% below our estimate - increases zinc and copper production by combining mature assets with new developments.
• Company 2 - 30% below our estimate - supplies specialized chips and software that support demanding digital infrastructure operations.
• Company 3 - 48% below our estimate - executes large public works contracts while navigating higher labor and technology input costs.

That is three of the list. See the full list of 189 companies trading below our fair value estimates →

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com